Dose Finding Study in COPD

Completed · Phase 2

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.

Key facts

Study ID

NCT00122434

Run by

Boehringer Ingelheim

People needed

389

Starts

2005-07-01

Last updated by the study team

2017-12-28

Who can join

Age: 40 and older, up to 83. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UAB Lung Health Center — Birmingham, Alabama, United States
• Vapahcs 111P — Palo Alto, California, United States
• Boehringer Ingelheim Investigational Site — San Diego, California, United States
• GLAHS Sepulveda — Sepulveda, California, United States
• Rehabilitation Clinical Trial Center — Torrance, California, United States
• Boehringer Ingelheim Investigational Site — Wheat Ridge, Colorado, United States
• Hospital for Special Care — New Britain, Connecticut, United States
• Bay Pines VA Medical Center — Bay Pines, Florida, United States
• Boehringer Ingelheim Investigational Site — Panama City, Florida, United States
• Boehringer Ingelheim Investigational Site — Pembroke Pines, Florida, United States
• Boehringer Ingelheim Investigational Site — Coeur d'Alene, Idaho, United States
• LSUHSC - Shreveport — Shreveport, Louisiana, United States
• VAMC-Reno — Reno, Nevada, United States
• North Shore Universtiy Hospital — New Hyde Park, New York, United States
• SVMMC — Toledo, Ohio, United States
• Boehringer Ingelheim Investigational Site — Medford, Oregon, United States
• Hershey Medical Center — Hershey, Pennsylvania, United States
• Boehringer Ingelheim Investigational Site — Philadelphia, Pennsylvania, United States
• Frank Sciurba — Pittsburgh, Pennsylvania, United States
• Boehringer Ingelheim Investigational Site — Charleston, South Carolina, United States
• MUSC — Charleston, South Carolina, United States
• Boehringer Ingelheim Investigational Site — Spartanburg, South Carolina, United States
• Boehringer Ingelheim Investigational Site — Harker Heights, Texas, United States
• MEDVAMC — Houston, Texas, United States
• McGuire VA — Fredericksburg, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.